@article {Arrieta403, author = {Oscar Arrieta and Francisco O. Garcia-Perez and David Michel-Tello and Laura-Alejandra Ram{\'\i}rez-Tirado and Quetzali Pitalua-Cortes and Graciela Cruz-Rico and Eleazar-Omar Macedo-P{\'e}rez and Andr{\'e}s F. Cardona and Jaime de la Garza-Salazar}, title = {Response Assessment of 68Ga-DOTA-E-[c(RGDfK)]2 PET/CT in Lung Adenocarcinoma Patients Treated with Nintedanib Plus Docetaxel}, volume = {59}, number = {3}, pages = {403--409}, year = {2018}, doi = {10.2967/jnumed.117.192393}, publisher = {Society of Nuclear Medicine}, abstract = {Nintedanib is an oral angiokinase inhibitor used as second-line treatment for non{\textendash}small cell lung cancer. New radiotracers, such as 68Ga-DOTA-E-[c(RGDfK)]2, that target αvβ3 integrin might have an impact as a noninvasive method for assessing angiogenesis inhibitors. Methods: From July 2011 through October 2015, 38 patients received second-line nintedanib plus docetaxel. All patients underwent PET/CT with 68Ga-DOTA-E-[c(RGDfK)]2 radiotracer and blood-sample tests to quantify angiogenesis factors (fibroblast growth factor, vascular endothelial growth factor, and platelet-derived growth factor AB) before and after completing 2 therapy cycles. Results: Of the 38 patients, 31 had available baseline and follow-up PET/CT. Baseline lung tumor volume addressed with 68Ga-DOTA-E-[c(RGDfK)]2 PET/CT correlated with serum vascular endothelial growth factor levels, whereas baseline lung/liver SUVmax index correlated with platelet-derived growth factor AB. After treatment, the overall response rate and disease control rate were 7.9\% and 47.3\%, respectively. A greater decrease in lung tumor volume (-37.2\% vs. {\textendash}27.6\%) was associated with a better disease control rate in patients (P = 0.005). Median progression-free survival was 3.7 mo. Nonsmokers and patients with a higher baseline lung tumor volume were more likely to have a higher progression-free survival (6.4 vs. 3.74 [P = 0.023] and 6.4 vs. 2.1 [P = 0.003], respectively). Overall survival was not reached. Patients with a greater decrease in lung SUVmax (not reached vs. 7.1 mo; P = 0.016) and a greater decrease in the lung/spleen SUVmax index (not reached vs. 7.1; P = 0.043) were more likely to have a longer overall survival. Conclusion: 68Ga-DOTA-E-[c(RGDfK)]2 PET/CT is a potentially useful tool for assessing responses to angiogenesis inhibitors. Further analysis and novel studies are warranted to identify patients who might benefit from this therapy.}, issn = {0161-5505}, URL = {https://jnm.snmjournals.org/content/59/3/403}, eprint = {https://jnm.snmjournals.org/content/59/3/403.full.pdf}, journal = {Journal of Nuclear Medicine} }